Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Ruth Johnson v. OptumRX Inc. et al
Case Number:
8:17-cv-00900
Court:
Nature of Suit:
Racketeer/Corrupt Organization
Multi Party Litigation:
Class Action
Judge:
Firms
Companies
Sectors & Industries:
-
September 18, 2017
Novo Nordisk, Benefits Co. Get Price Hike Suit Moved To NJ
A California federal judge agreed Monday to transfer to New Jersey a proposed class action accusing drugmaker Novo Nordisk Inc. and pharmacy benefit manager OptumRx Inc. of conspiring to drive up the price of Novo Nordisk's diabetes drug Victoza, noting that five suits over similar schemes have already been filed in New Jersey federal court.
-
August 08, 2017
Novo Nordisk, Benefits Co. Want Price Hike Fight Sent To NJ
Novo Nordisk Inc. and pharmacy benefits manager OptumRx Inc. on Monday urged a California federal judge to transfer the putative class action accusing them of inflating prices for a diabetes medication to New Jersey, where five nearly identical suits are already pending.
-
May 24, 2017
Novo Nordisk, Benefit Co. Conspired To Hike Prices, Suit Says
Drugmaker Novo Nordisk Inc. and pharmacy benefit manager OptumRx Inc. have conspired to artificially inflate the price of a Type 2 diabetes medication, forcing patients to pay more than they normally would for the treatment, according to a proposed class action filed Tuesday in California federal court.